FAST study: Feasibility ASessment of circulating Tumour DNA (ctDNA) in the diagnosis of advanced lung cancer in patients

niversity of Otago0 个研究点目标入组 50 人开始时间: 2024年4月15日最近更新: 2024年8月12日

适应症

试验速览

暂无简介。

•1.Participant is willing and able to give informed consent for participation in the trial.
•2.Male or female, aged 18 years or above.
•3.Radiological advanced lung cancer (distant metastases as per American Joint Committee on Cancer (AJCC) 8th edition Tumour, Nodes, Metastasis (TNM) staging, stage M1a, M1b or M1c)
•4.Radiologist confirmed suspicion of malignancy on chest X-Ray (CXR) or computerised tomography (CT) and clinician opinion likely lung cancer primary
•5.Not suitable for cytotoxic chemotherapy but fit for molecularly targeted treatment, due to patient comorbidity, performance status or patient preference
•6.Unable to pursue molecular testing of a histological sample
•a.Due to anatomical location/risk of complications or,
•b.Due to patient preference or,
•c.Due to insufficient material for molecular testing
•7.Life expectancy expected more than 4 weeks
•8.In the Investigator’s opinion, is able and willing to comply with all trial requirements.
•9.Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the trial.

•European Cooperative Oncology Group Performance status (ECOG PS) 4
•Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial.

发起方